GLP-2TZ
GLP-2TZ is a dual agonist peptide that activates the GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. By activating both incretin pathways, it enhances glucose-dependent insulin secretion, decreases glucagon activity when glucose is elevated, slows gastric emptying, and reduces appetite. All of these effects combined facilitates substantial weight loss.
Key Benefits
Substantial Weight Reduction: Proven to facilitate significant reductions in body weight and adiposity.
Appetite Regulation: GLP-1 and GIP receptor activity can reduce energy intake, increase satiety, and support appetite control.
Improved Glycemic Control: Incretin receptor activation enhances glucose-dependent insulin secretion and supports healthy glucose regulation.
Improved Insulin Sensitivity: Weight reduction and incretin activity can improve markers of insulin resistance and metabolic health.
Reduced Glucagon Secretion: GLP-1 receptor activation can suppress inappropriate glucagon secretion in a glucose-dependent manner, supporting glucose control.
Metabolic Health: Tirzepatide has demonstrated improvements in several cardiometabolic measures alongside reductions in body weight.
Compound Class: Dual GLP-1 and GIP Agonist
CAS Number: 2023788-19-2
Molecular Formula: C₂₂₅H₃₄₈N₄₈O₆₈
Molecular Weight: 4813.5 g/mol
Form: Lyophilized Powder
Storage: Store in a cool, dark environment away from light. Avoid repeated temperature swings.
Lyophilized Powder Vial - Keep frozen between -2F to -4F
Reconstituted Liquid Vial - Keep refrigerated between 36F to 40F. Do NOT freeze.
Disclaimer: These products are intended for research or laboratory use only. Not for human or veterinary consumption.
These statements have not been reviewed by the FDA nor are they medical advice. Retailer is not responsible for injury or death. Always consult with a licensed health professional for medical advice.
